Floatz logo

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661

Solid Tumors

Hoffmann-La Rochemonoclonal_antibodyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

928 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661 is also rated in:

esophageal squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
metastatic melanomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →